.png){kind=icon}
.png){kind=icon}
Return
Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
.png){kind=icon}
PRE
AI
P
V
M
M
A
M
L
J
DOI：10.1016/s0140-6736(26)01247-x.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Zenagamtide (formerly amycretin) is a unimolecular peptide agonist of GLP-1, amylin, and calcitonin receptors. We aimed to investigate the dose–response relationship with respect to the efficacy and safety of once-daily oral zenagamtide compared with placebo in adults with type 2 diabetes.
Journal
IF:
88.5
Papers:
5.4W
Citations:
34.8W
Organization
Cited Papers